Repertoire Immune Medicines has dosed the first participant in a Phase I/II clinical trial of RPTR-1-201, a novel TCR bispecific therapy designed to treat advanced solid tumours.  

The trial is being conducted at multiple clinical sites in the United States and Europe following clearance of Repertoire’s Investigational New Drug (IND) application by the US Food and Drug Administration and authorisation via the Clinical Trials Information System (CTIS) in Europe. 

“T cell-targeted immune medicines have shown they can drive deep and durable responses in some cancers, yet many patients with advanced solid tumours still have limited treatment options,” said Robert Andtbacka, Chief Medical Officer of Repertoire. “RPTR-1-201 is designed to direct a patient’s own T cells toward a shared, tumour-selective target. Dosing the first participant is a major milestone for Repertoire and the start of evaluating RPTR-1-201’s safety and potential benefit in the clinic.” 

RPTR-1-201 is a TCR bispecific molecule comprised of an engineered TCR that binds with high affinity and precision to a tumour-selective epitope and an anti-CD3 moiety that engages and redirects T cells to kill tumour cells. In preclinical studies, RPTR-1-201 has demonstrated potent killing of both immunologically ‘hot’ and ‘cold’ tumours and a favourable preclinical safety profile.  

Unlike many other T cell-targeted approaches that focus on well-known antigens specific to a single tumour type, RPTR-1-201 binds to a novel epitope discovered using Repertoire’s DECODETM platform that is shared across multiple solid tumours and may be relevant for as many as 200,000 patients with metastatic or unresectable cancer each year in the US and Europe. 

Anthony Coyle, President, Research and Development at Repertoire, said: “The initiation of this trial marks an important milestone, as RPTR-1-201 is the first validation of our ability to convert immune codes into potential immune medicines for cancer.”